Brief overview of peri-operative antiplatelet therapy BJA 2007; 99(3) : 316-28 Nov 9 th 2010 M. Cunningham.

Slides:



Advertisements
Similar presentations
Monitoring platelet function using the Multiplate® analyzer
Advertisements

Stroke Impact It was then that it happened. To my shock and incredulity, I could not speak. That is, I could utter nothing intelligible. All that would.
Platelet Aggregation Inhibitors
MANAGEMENT OF CARDIAC SURGICAL PATIENTS RECEIVING PLATELET INHIBITORS
Update on the Medical Management of Acute Coronary Syndrome.
Oral Antiplatelet Agents: A Cornerstone of Therapy for Atherothrombotic Disease Aspirin and clopidogrel: - Reduce the risks of myocardial infarction, ischemic.
Antiplatelets Dr. Ahmed Amin FCARCSI Arab Board M. Sc.
Long-term Outcomes of Patients with ACS and Chronic Renal Insufficiency Undergoing PCI and being treated with Bivalirudin vs UFH/Enoxaparin plus a GP IIb/IIIa.
ANESTHESIA FOR NON CARDIAC SURGERY IN PATIENTS WITH CORONARY STENTS
Antiplatelet Drugs (Anti-thrombotics)
1 Update on antiplatelet and anticoagulant drugs: sticky stuff KFJ Ng May 2011.
Combination Therapy in Acute Coronary Disease Elizabeth Gabrielle PA-S Lock Haven University February 2009.
Point of Care Platelet Function Testing – Is There Still Value?
Effect of Clopidogrel Premedication in Off-Pump Cardiac Surgery Emmanouil I. Kapetanakis, MD; Diego A. Medlam, MD; Kathleen R. Petro, MD; Elizabeth Haile,
Giovanni Maria Santoro S. C. Cardiologia Ospedale San Giovanni di Dio Firenze Gestione del paziente con stent coronarico. Il mantenimento della doppia.
ANTIPLATELET DRUGS.
ASPIRIN ↓ Cox inhibition ↓ (PROSTACYCLIN) PGI 2 & TXA 2 (THROMBOXANE) LOW DOSE ASPIRIN.
Glycoprotein IIb/IIIa inhibitors and bivalirudin: under utilised? Azfar Zaman Freeman Hospital Newcastle-upon-Tyne.
Do Tirofiban And ReoPro Give Similar Efficacy Outcomes Trial Presented at AHA Scientific Sessions Nov. 15, 2000.
ANTIPLATELET DRUGS Learning objectives By the end of this lecture, students should be able to: - describe different classes of anti-platelet drugs and.
PJ Devereaux, Population Health Research Institute, Hamilton, Canada on behalf of POISE-2 Investigators PeriOperative ISchemic Evaluation-2 Trial POISE-2POISE-2.
Antiplatelet drugs Prof. Hanan Hagar Learning objectives By the end of this lecture, students should be able to to describe different classes of anti-platelet.
PRODIGY Objective Study Design Primary Composite Endpoint
Antiplatelet drugs Dr.V.V.Gouripur. Antiplatelet drug An antiplatelet drug is a member of a class of drugs that decreases platelet aggregation and inhibits.
Anesthetic management of patients with coronary stents Dr. S. Parthasarathy MD, DA, DNB, Dip Diab.MD,DCA, Dip software based statistics, PhD (physiology)
The Leeds Teaching Hospitals NHS Trust PHARMACOLOGY IN ACS OVERVIEW OF THE DATA : PRACTICAL ADVICE JIM McLENACHAN, LEEDS. 25 th January, 2007.
Trial Vignettes Cameron G Densem TRITON-TIMI 38 ARMYDA OPTIMA.
Jong-Yoon Yi, MD, FACC President, Heartland Education & Research Foundation.
수요저널 우종신. ACC/AHA Guideline Focused Update 2011 Class I 1. After PCI, use of aspirin should be continued indefinitely. (Level of Evidence.
II. Antiplatelet Drugs.
The management of anti-thrombotics in patients undergoing GI endoscopy
Canadian Cardiovascular Society Antiplatelet Guidelines
The American College of Cardiology Presented by Dr. Adnan Kastrati
Title Introduction Methods Results Discussion Authors
Algorithm for preoperative management of patients taking antiplatelet therapy. ACS, acute coronary syndrome; BMS, bare metal stent; DES, drug-eluting stent;
M. Valgimigli University of Ferrara Italy
Polypharmacy Anticoagulation: AF meets PCI
For the HORIZONS-AMI Investigators
Management of ST-Elevation Myocardial Infarction
Why Radial Access Should be the Default for Women undergoing PCI?
POISE-2 PeriOperative ISchemic Evaluation-2 Trial
Preventing Thrombotic Complications in ACS: State of the Art
ACTIVE A Effects of Addition of Clopidogrel to Aspirin in Patients with Atrial Fibrillation who are Unsuitable for Vitamin K Antagonists.
Achieving Long-Term Protection Post-MI
The following slides highlight a review of a presentation at the 16th World Congress of the World Society of Cardio-Thoracic Surgery (WSCTS) in Ottawa,
Introduction Antiplatelet Agents ADP Receptor Antagonists.
טיפול עם נוגדי טסיות ד"ר ראובן מוזס רחל.
Natural History of Atherothrombosis Finding the Right Risk-Benefit Balance.
Antithrombotics and PAD: A New Paradigm in Practice
NOACS: Emerging data in ACS/IHD
AF and PCI in Practice.
Comparison of US and European Guidelines Oral Antiplatelet Therapy in Primary PCI/STEMI.
Section F: Clinical guidelines
Section D: Clinical trial update: GP IIb/IIIa inhibition
Perioperative management of antiplatelet therapy
For the HORIZONS-AMI Investigators
For the HORIZONS-AMI Investigators
Perioperative antiplatelet therapy: the case for continuing therapy in patients at risk of myocardial infarction  P.-G. Chassot, A. Delabays, D.R. Spahn 
Duration of Dual Antiplatelet Therapy
Impact of Platelet Reactivity Following Clopidogrel Administration
Factor Xa Inhibitors in PAD
Erasmus MC, Thoraxcenter
Anemia Is Associated With Increased One-Year Mortality and Ischemic Events in Patients With ACS: Results From the ACUITY Trial Steven V. Manoukian, George.
Roberta Rossini et al. JCIN 2018;11:
Anti-Platelet Drugs Dr. A. Shyam Sundar. M.Pharm., Ph.D,
ESC Guideline on the Management of STEMI Recommendation for DAPT
Section C: Clinical trial update: Oral antiplatelet therapy
P2Y12 receptor inhibitor therapy for secondary prevention of patients with stable coronary artery disease. P2Y12 receptor inhibitor therapy for secondary.
Presentation transcript:

Brief overview of peri-operative antiplatelet therapy BJA 2007; 99(3) : Nov 9 th 2010 M. Cunningham

Standard approach ● Simple ● Complicated by ● Rebound effects ● Prothrombotic effects of surgery ● PCI Stop antiplatelet dugs 7-10 days before surgery

Complicated problem ! ● Used for primary and secondary prevention ● > 2 million PCI p.a. in Western Countries. 5% have non-cardiac surgery with 1 year. ● BMS ● DES ● Risk varies with time ● Various agents ● COX ● ADP ● GP IIb/IIIa What is safe ?

Antiplatelet agents ● COX-1 antagonist Irreversible - Aspirin Reversible – Ibuprofen etc. ● ADP receptor antagonists Clopidogrel ● GP IIb/IIIa antagonists Abciximab / tirofiban / eptifibatide

PCI – Risk of non-cardiac surgery Earl y MI 30% Mortality 20-40% 5-10 fold increase ? Aspirin lifelong

Why stop clopidogrel ?

BMS v DES

So just carry on ? ● Aspirin ● Dual therapy ● No CI to CNB ● Increases risk of haemorrhage by 1.5 but not morbidity. ● Surgeons unable to differentiate. ● Transfusion rate increased by 1.5x in orthopaedics. ● Problems in tonsillectomy (7.2x re- operation) and TURP (2.7x transfusion rate). ● Intra-cranial surgery - danger

So just carry on ? ● Aspirin ● Dual therapy ● Evidence poor ● In general: ● Blood loss likely to increase by % ● Little impact in transfusion rate (38.5% v 42.6% in selected, major, non-cardiac surgery) ● No impact on morbidity, mortality or outcome. ● Neurosurgery: Fatalities reported with intra-cranial procedures.

Summary

Risk factors

Questions ?

Timing ● Aspirin 8.5 days to ACS 14.3 days to CVA